Hovione shows off Irish API plant
API maker Hovione’s manufacturing facility in Cork, Ireland was unveiled at an opening ceremony yesterday just two weeks after the previous owner, global drug giant Pfizer, formally handed over the keys.
Trial of nanoparticle delivered anti-cancer gene progresses
Research has been presented on the first Phase I trials of a systemic, non-viral, targeted nanoparticle that delivers a p53 tumour suppressor gene to combat cancer.
Winpak’s Q1 profits soar despite falling sales
Winpak appears to have benefited from the current economic turmoil, with lower raw material costs and favourable currency rates helping it post net earnings of $9.7m (€7.4m), up by 62 per cent on 2008.
Project cancellations dominate Kendle’s gloomy Q1 forecast
US firm Kendle is the latest CRO to revise its forecast and blame “unprecedented biopharmaceutical industry conditions,” which are fast becoming an industry catchphrase, for its Q1 woes.
IntelGenx furthers novel antihypertensive formulation
IntelGenx’ clinical pilot study indicates the bioequivalence of a leading antihypertensive and its product, which has been developed using its multilayer Versatab delivery technology.
Movement at Pfizer, Solvay and Biovail – People on the move
in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical industry, including movement at Pfizer, Solvay and Biovail.
Bio-Path calls in Acorn to help with siRNA drug trial
Bio-Path Holdings has called in US CRO Acorn to provide a contract medical officer for a study of its candidate antisense cancer drug liposomal Grb-2.
“Unprecedented cancellation levels” dent PPD’s earnings
PPD’s revenues dipped in Q1 as the company was hit by contract cancellations totaling $215m (€166m), which included a $77m deal with a large biotech for a multinational clinical trial.
Plucked hair model could help smooth drug development path
Epistem claims its “plucked hair biomarker model” provides drugmakers with minimally invasive way monitoring epithelial response to cancer candidates that can significantly reduce development times.
India assesses if patent laws would violate TRIPS
A committee appointed by the Indian government has submitted a report into whether patent issues around microorganisms and NCEs are in compliance with TRIPS.
GSK to buy Stiefel for $2.93bn
GlaxoSmithKline’s (GSK) $2.9bn (€1.8bn) cash acquisition of US skin drug specialist Stiefel Laboratories “re-energises” the UK firm’s dermatology range, according to CEO Andrew Witty.
Sanofi investment targets China’s diabetes market
Sanofi-Aventis is investing a further $90m in its Chinese manufacturing facility and performing “the world’s largest diabetes genotyping project” in partnership with the Chinese Diabetes Society.
Aoxing’s pain drug plant gets GMP OK
China Aoxing Pharmaceutical, a specialist developer of pain management drugs, has received GMP accreditation for the new tablet production and packaging plant it has set up in Shijiazhuang.
PhRMA revises principles to increase transparency
Following calls for increased transparency PhRMA has published its new clinical trial principles, which contain revisions relating to registration, authors and sponsor disclosure.
Siro ClinPharm and ACT team up on oncology
Indian CRO Siro ClinPharm is teaming up with New Jersey based pharma services firm Advanced Clinical Trial Solutions (ACT) to strengthen its position in the US cancer trial sector.